Increased R&D expenses led to a higher net loss in 2010 for radioisotope manufacturer International Isotopes.
For the year (end-December 31), International Isotopes had revenue of $6.11 million, down 1% compared with the $6.12 million reported in 2009. The firm pointed to sales dips in its nuclear medicine standards, radiological services, and transportation services segments for the small revenue decrease.
The company had a net loss of $6.8 million, compared with a net loss of $4.6 million in 2009. The increased net loss was primarily attributable to the R&D expense related to the U.S. Nuclear Regulatory Commission (NRC) licensing review costs and expanded engineering work incurred on its planned uranium deconversion facility, according to International Isotopes.
